Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Towards a “fourth 90”: A population-based analysis of post-tuberculosis pulmonary function testing in British Columbia, Canada, 1985–2015

C. Andrew Basham, Victoria J. Cook, James C. Johnston
European Respiratory Journal 2020 56: 2000384; DOI: 10.1183/13993003.00384-2020
C. Andrew Basham
1School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada
2British Columbia Centre for Disease Control, Vancouver, BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: umbashac@myumanitoba.ca
Victoria J. Cook
2British Columbia Centre for Disease Control, Vancouver, BC, Canada
3Division of Respiratory Medicine, University of British Columbia, Vancouver, BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James C. Johnston
1School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada
2British Columbia Centre for Disease Control, Vancouver, BC, Canada
3Division of Respiratory Medicine, University of British Columbia, Vancouver, BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Post-tuberculosis lung disease is a growing concern globally. In a Canadian sample, only 3% of respiratory TB cases underwent pulmonary function testing within 90 days of treatment end. Benchmarks for post-TB pulmonary function testing are needed. https://bit.ly/2WX3tVf

To the Editor:

Mounting evidence of chronic obstructive and restrictive lung disease among respiratory tuberculosis (TB) patients after treatment [1–4] raises questions about current practice in terms of linkage to care once pharmacologic treatment for TB has stopped. A systematic review of post-TB COPD showed pooled odds ratio of 3.05 (95% CI 2.42–3.85) for people with a history of TB compared to non-TB controls [3]. Another review reported a range of proportions of TB patients with airflow obstruction post-TB of 0.18–0.87 [1]. The development of a “fourth 90”, in addition to the three objectives of the Stop TB Partnership's Global Plan to End TB, has been suggested: “Ensuring that 90% of all people successfully completing treatment for TB can have a good health-related quality of life” [5]. Post-TB sequelae may figure prominently in reductions in quality of life among TB patients [6], particularly those with severe forms of pulmonary TB [7]. International guidelines on TB treatment provide limited, if any, guidance for managing post-TB sequelae [8]. A logical first step towards managing post-TB lung disease (PTBLD) in well-resourced programmes may be to measure pulmonary function at the end of TB treatment. This may be performed at relatively low cost and with virtually no risk to the patient or public. The proportion of respiratory TB patients in high-resource settings who undergo pulmonary function testing during or after TB treatment is unknown. We hypothesised that a small proportion received this form of diagnostic testing in our well-resourced local setting (British Columbia (BC), Canada).

We used a large retrospective cohort of immigrants to BC, Canada, arriving from 1985–2012, which has been described elsewhere [9]. This linked administrative database contains health administrative data on all TB patients diagnosed and treated in BC during the period 1985–2015. This database was used to analyse the proportion of respiratory TB patients receiving pulmonary function testing in BC near the end of their TB treatment. For this analysis, we assembled all medical services plan (MSP) physician and technical fee-for-service claims related to components of pulmonary function testing from 1 January, 1985 to 31 December, 2015. We then assembled a retrospective cohort of people diagnosed with laboratory-confirmed respiratory TB who had successful treatment completion documented in the BC TB registry. Ethics approval was granted by the University of British Columbia (H16-00265).

Pulmonary function testing was defined as a minimum of one MSP billing claim within 90 days of TB treatment completion date (before or after) for any of the following services, including either the physician or technical fee claims: spirometry (with and without bronchodilators), flow volume loops and logs (with and without brochodilators), peak expiratory flow rate, lung volumes, diffusion studies, and detailed pulmonary function testing [10]. In addition to 90 days, we established two further indicator variables for pulmonary function testing at 180 days and 365 days (excluding pulmonary function tests prior to TB treatment initiation) to test the robustness of our main analysis measure to relaxation of the timing condition. We also calculated the mean, median and interquartile range (IQR) for days from TB treatment completion date to pulmonary function test date for those with pulmonary function testing anytime post-TB treatment initiation.

A total of 1376 respiratory TB patients with treatment completion, within our immigration cohort, were identified in the BC TB registry (table 1). For our primary measure of post-TB pulmonary function testing, we found that, within 90 days of the treatment completion date, only 2.9% of respiratory TB patients underwent testing. This percentage rose to 4.9% within 180 days, 7.0% within 365 days, and 14.2% at any time post-TB treatment initiation (table 1). Among the 14.2% with pulmonary function testing at any time post-TB treatment initiation, the mean difference in days between TB treatment completion date and pulmonary function testing date was 1810 days (∼5 years), with a median of 1297 days (IQR 387–2623 days). Respiratory TB patients who were female, or had higher levels of comorbidity, or were at older age when treatment was initiated, each had higher likelihood of pulmonary function testing during or after TB treatment (table 1).

View this table:
  • View inline
  • View popup
TABLE 1

Respiratory tuberculosis (TB) patients undergoing pulmonary function testing after TB treatment initiation: immigrants to British Columbia, Canada, 1985–2015

The results of this analysis suggest a large gap in post-TB respiratory care in Canada. It is unclear if the findings would be similar in other high-income jurisdictions. However, we note a lack of standards of care for lung function testing among TB patients and a lack of guidance from international guidelines [8]. Moreover, in low-resource regions, lung function testing is infrequently available in health centres where people receive TB treatment [11]. Benchmarks for PTBLD prevention, diagnosis, and care are needed to assess progress towards a “fourth 90” in various settings.

Results from the BOLD study show significant obstructive and restrictive sequelae among TB survivors [12]. Understanding the degree of pulmonary impairment in a TB survivor may lead to immediate benefits in terms of interventions and therapeutics. For example, pneumococcal vaccination may be appropriate for individuals with significant post-TB airway disease. Additionally, pulmonary rehabilitation has been associated with lung function improvement in people with post-TB pulmonary sequelae [13]. Using spirometry results as a marker of “lung age” may also serve as a motivational tool for TB survivors to quit smoking [14]. Meanwhile, pharmacological interventions, such as long-acting muscarinic antagonists or long-acting β-agonists, require further investigation in patients with post-TB airway disease given the likely difference in pathophysiology.

As the post-TB health agenda progresses [5, 15], TB programmes in high-resource settings may wish to conduct similar analyses to determine baseline service levels for PTBLD prevention, diagnosis, and care. Health services research studies that integrate data from the broader health system with TB registry-type data are needed to understand patterns of health service use among TB patients post-TB treatment completion. In Canada, TB programmes may be able to access similar data to track post-TB pulmonary function testing, which may inform guideline development and performance targets for post-TB care [5]. Such studies may also seek to identify care trajectories before and after TB diagnosis that may elucidate points for prevention and intervention to reduce the burden of TB and lung disease among the TB survivors. Furthermore, economic valuations of TB prevention activities, including vaccine development, prophylactic testing and treatment, as well as earlier detection, may appear more appealing if post-TB pulmonary conditions are incorporated into economic and policy evaluation models [16]. Collaborations between TB programmes and primary care could provide valuable context for implementation of any new guidelines developed for post-TB lung function testing.

Towards the goal of increasing post-TB pulmonary function testing in BC, the authors plan to establish a Partnership for Post-TB Health. This partnership aims to create a focused knowledge exchange and models of care development network within the BC Centre for Disease Control that will monitor and generate evidence on post-TB health and interventions. We invite collaboration from other TB researchers, around Canada particularly, in this effort.

Shareable PDF

Supplementary Material

This one-page PDF can be shared freely online.

Shareable PDF ERJ-00384-2020.Shareable

Footnotes

  • All inferences, opinions, and conclusions drawn in this manuscript are those of the authors, and do not reflect the opinions or policies of the data stewards.

  • Author contributions: C.A. Basham, V.J. Cook and J.C. Johnston designed the study. C.A. Basham conducted the data analysis and interpretation. C.A. Basham drafted the manuscript. J.C. Johnston and V.J. Cook provided critical review comments and additional intellectual content. All authors approved the final manuscript. We gratefully acknowledge the comments of Faiz Ahmad Khan on an earlier draft.

  • Conflict of interest: C.A. Basham reports grants from Canadian Institutes for Health Research, during the conduct of the study.

  • Conflict of interest: V.J. Cook has nothing to disclose.

  • Conflict of interest: J.C. Johnston reports grants from Canadian Institutes for Health Research and Michael Smith Foundation for Health Research, during the conduct of the study.

  • Support statement: This project was supported by Canadian Institutes for Health Research (CIHR) Project (PJT #153213), which funded data access. CAB is supported by CIHR (PJT #153213). JCJ is supported by the Michael Smith Foundation for Health Research (MSFHR) and CIHR (PJT #153213). Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received February 21, 2020.
  • Accepted March 24, 2020.
  • Copyright ©ERS 2020
https://www.ersjournals.com/user-licence

References

  1. ↵
    1. Ravimohan S,
    2. Kornfeld H,
    3. Weissman D, et al.
    Tuberculosis and lung damage: From epidemiology to pathophysiology. Eur Respir Rev 2018; 27: 170077. doi:10.1183/16000617.0077-2017
    OpenUrlAbstract/FREE Full Text
    1. Osman M,
    2. Welte A,
    3. Dunbar R, et al.
    Morbidity and mortality up to 5 years post tuberculosis treatment in South Africa: A pilot study. Int J Infect Dis 2019; 85: 57–63. doi:10.1016/j.ijid.2019.05.024
    OpenUrl
  2. ↵
    1. Byrne AL,
    2. Marais BJ,
    3. Mitnick CD, et al.
    Tuberculosis and chronic respiratory disease: a systematic review. Int J Infect Dis 2015; 32: 138–146. doi:10.1016/j.ijid.2014.12.016
    OpenUrlCrossRefPubMed
  3. ↵
    1. Allwood B,
    2. van der Zalm M,
    3. Makanda G, et al.
    The long shadow post-tuberculosis. Lancet Infect Dis 2019; 19: 1170–1171. 10.1016/S1473-3099(19)30564-X.
    OpenUrl
  4. ↵
    1. Harries AD,
    2. Dlodlo RA,
    3. Brigden G, et al.
    Should we consider a ‘fourth 90’ for tuberculosis? Int J Tuberc Lung Dis 2019; 23: 1253–1256. 10.5588/ijtld.19.0471.
    OpenUrl
  5. ↵
    1. Laxmeshwar C,
    2. Stewart AG,
    3. Dalal A, et al.
    Beyond ‘cure’ and ‘treatment success’: quality of life of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2019; 23: 73–81. 10.5588/ijtld.18.0149.
    OpenUrl
  6. ↵
    1. Tiberi S,
    2. Torrico MM,
    3. Rahman A, et al.
    Managing severe tuberculosis and its sequelae: from intensive care to surgery and rehabilitation. J Bras Pneumol 2019; 45: 1–9. doi:10.1590/1806-3713/e20180324
    OpenUrl
  7. ↵
    1. Wanner A,
    2. Edwards M,
    3. Harries AD, et al.
    International research and guidelines on post-tuberculosis chronic lung disorders: a systematic scoping review. BMJ Glob Heal 2018; 3: 1–8. doi:10.1136/bmjgh-2018-000745
    OpenUrl
  8. ↵
    1. Ronald LA,
    2. Campbell JR,
    3. Balshaw RF, et al.
    Predicting tuberculosis risk in the foreign-born population of British Columbia, Canada: study protocol for a retrospective population-based cohort study. BMJ Open 2016; 6: e013488. doi:10.1136/bmjopen-2016-013488.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. British Columbia Ministry of Health, Health Sector Information, Analysis and Reporting Division
    . MSP Fee-For-Service Payment Analysis 2014/2015 - 2018/2019. https://www2.gov.bc.ca/assets/gov/health/practitioner-pro/medical-services-plan/ffs_complete.pdf
  10. ↵
    1. Harries AD,
    2. Chakaya JM
    . Assessing and managing pulmonary impairment in those who have completed TB treatment in programmatic settings. Int J Tuberc Lung Dis 2019; 23: 1044–1045. 10.5588/ijtld.19.0168.
    OpenUrl
  11. ↵
    1. Amaral AFS,
    2. Coton S,
    3. Kato B, et al.
    Tuberculosis associates with both airflow obstruction and low lung function: BOLD results. Eur Respir J 2015; 46: 1104–1112. doi:10.1183/13993003.02325-2014
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Visca D,
    2. Zampogna E,
    3. Sotgiu G, et al.
    Pulmonary rehabilitation is effective in patients with tuberculosis pulmonary sequelae. Eur Respir J 2019; 53: 1802184. 10.1183/13993003.02184-2018.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Westerdahl E,
    2. Arne M,
    3. Larsson M, et al.
    Spirometry to motivate smoking cessation – a systematic review. Eur Respir J 2018; 52: Suppl. 62, PA1734. doi:10.1183/13993003.congress-2018.PA1734
    OpenUrlCrossRef
  14. ↵
    1. Basham CA,
    2. Romanowski K,
    3. Johnston JC
    . Life after tuberculosis: planning for health. Lancet Respir Med 2019; 7: 1004–1006. 10.1016/S2213-2600(19)30371-6.
    OpenUrl
  15. ↵
    1. Quaife M,
    2. Houben RMGJ,
    3. Allwood B, et al.
    Post-tuberculosis mortality and morbidity: valuing the hidden epidemic. Lancet Respir Med 2020; 8: 332–333. 10.1016/S2213-2600(20)30039-4.
    OpenUrl
PreviousNext
Back to top
View this article with LENS
Vol 56 Issue 2 Table of Contents
European Respiratory Journal: 56 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Towards a “fourth 90”: A population-based analysis of post-tuberculosis pulmonary function testing in British Columbia, Canada, 1985–2015
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Towards a “fourth 90”: A population-based analysis of post-tuberculosis pulmonary function testing in British Columbia, Canada, 1985–2015
C. Andrew Basham, Victoria J. Cook, James C. Johnston
European Respiratory Journal Aug 2020, 56 (2) 2000384; DOI: 10.1183/13993003.00384-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Towards a “fourth 90”: A population-based analysis of post-tuberculosis pulmonary function testing in British Columbia, Canada, 1985–2015
C. Andrew Basham, Victoria J. Cook, James C. Johnston
European Respiratory Journal Aug 2020, 56 (2) 2000384; DOI: 10.1183/13993003.00384-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Shareable PDF
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Airway immune responses to COVID-19 vaccination in COPD patients
  • Wider access to rifapentine-based regimens is needed for TB care globally
  • Screening for PVOD in heterozygous EIF2AK4 variant carriers
Show more Agora

Research letters

  • Translated impact on carbon footprint from choice of inhaled therapy
  • Radiographic score in TB and relationship to therapy and bacillary load
  • Single-inhaler triple versus dual bronchodilator therapy for GOLD “E” COPD patients
Show more Research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society